Drug | fm CYP2D6a (Literature) | Metabolite Recoveryb (EM) | Estimated fm CYP2D6c | Estimated fm CYP2D6d (in Vitro) |
---|---|---|---|---|
Amitriptyline | 0.83 | 0.50 | 0.42 | 0.53 ± 0.03 |
Atomoxetine | >0.90 | 0.87 | 0.87 | 0.97 ± 0.04 |
Desipramine | Majore | 0.68 | 0.68 | 0.80 ± 0.08 |
Dextromethorphan | Majore | N.D.f | 0.90 | 0.93 ± 0.04 |
Duloxetine | Majore | 0.50 | 0.50 | 0.87 ± 0.06 |
Imipramine | 0.80 | 0.44 | 0.35 | 0.67 ± 0.03 |
Propafenone | N.D. | >0.70f | 0.70 | 0.74 ± 0.03 |
Propranolol | 0.40 | 0.42 | 0.17 | 0.76 ± 0.03 |
Sertraline | <0.20-0.35 | N.D.f | 0.32 | 0.37 ± 0.04 |
Tolterodine | Majore | 0.70 | 0.70 | 0.79 ± 0.03 |
Venlafaxine | Majore | 0.72 | 0.72 | 0.85 ± 0.07 |
N.D., not determined.
↵ a Estimated conversion to specific metabolite(s) catalyzed by CYP2D6 in vitro.
↵ b Metabolite(s) recovery in vivo for CYP2D6 products taken from Dorne et al. (2002).
↵ c Calculated as the product of the fractional conversion by CYP2D6 taken from the literature and metabolite recovery in EM subjects.
↵ d Fraction metabolized by CYP2D6 using microsomal incubations measuring substrate depletion with and without 1 μM quinidine.
↵ e For drugs with a major contribution by CYP2D6 in vitro, a value of 1 was used for the calculation of estimated fraction metabolized by CYP2D6 in vivo.
↵ f For drugs without metabolite recovery data reported in the literature, a value of 0.90 was used for the calculation of estimated fraction metabolized by CYP2D6 in vivo.